Current Opinion in Investigational Drugs 2004-09-01

ETC-588 (Pfizer).

Sheila A Doggrell

Index: Curr. Opin. Investig. Drugs 5(9) , 993-9, (2004)

Full Text: HTML

Abstract

Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.